Evidence map›Paper›PMID 32820045›Full record

ArticleThe Journal of biological chemistry2020

Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite.

Minervo Perez, Daniel W Bak, Sarah E Bergholtz, Daniel R Crooks, Bhargav Srinivas Arimilli, Youfeng Yang, Eranthie Weerapana, W Marston Linehan, Jordan L Meier

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Minervo PerezChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.
Daniel W BakDepartment of Chemistry, Boston College, Chestnut Hill, Massachusetts, USA.
Sarah E BergholtzChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.
Daniel R CrooksUrologic Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland, USA.
Bhargav Srinivas ArimilliUrologic Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland, USA.
Youfeng YangUrologic Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland, USA.
Eranthie WeerapanaDepartment of Chemistry, Boston College, Chestnut Hill, Massachusetts, USA.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland, USA.
Jordan L MeierChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA. Electronic address: jordan.meier@nih.gov.
National Institutes of Health · USBoston College · US

Funding

Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Targeting Cancer Through Modifications and MetabolismZIABC011488 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MEIER, JORDAN L · 2013 to 2025
$21.3M
Developing chemical-proteomic tools to investigate cysteine oxidationR35GM134964 · NIGMS · BOSTON COLLEGE · PI WEERAPANA, ERANTHIE · 2020 to 2024
$3.1M
Investigating cysteine-mediated protein activities in C. elegansR01GM118431 · NIGMS · BOSTON COLLEGE · PI WEERAPANA, ERANTHIE · 2015 to 2019
$1.8M
Investigating cysteine PTMs in living cellsR01GM117004 · NIGMS · BOSTON COLLEGE · PI WEERAPANA, ERANTHIE · 2016 to 2019
$1.2M
Intramural NIH HHS ZIA BC011038Intramural NIH HHS ZIA BC011488NIGMS NIH HHS R01 GM117004NIGMS NIH HHS R01 GM118431NIGMS NIH HHS R35 GM134964
6 · The paper itself

Abstract

An important context in which metabolism influences tumorigenesis is the genetic cancer syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a disease in which mutation of the tricarboxylic acid cycle enzyme fumarate hydratase (FH) causes hyperaccumulation of fumarate. This electrophilic oncometabolite can alter gene activity at the level of transcription, via reversible inhibition of epigenetic dioxygenases, as well as posttranslationally, via covalent modification of cysteine residues. To better understand the potential for metabolites to influence posttranslational modifications important to tumorigenesis and cancer cell growth, here we report a chemoproteomic analysis of a kidney-derived HLRCC cell line. Using a general reactivity probe, we generated a data set of proteomic cysteine residues sensitive to the reduction in fumarate levels caused by genetic reintroduction of active FH into HLRCC cell lines. This revealed a broad up-regulation of cysteine reactivity upon FH rescue, which evidence suggests is caused by an approximately equal proportion of transcriptional and posttranslational modification-mediated regulation. Gene ontology analysis highlighted several new targets and pathways potentially modulated by FH mutation. Comparison of the new data set with prior studies highlights considerable heterogeneity in the adaptive response of cysteine-containing proteins in different models of HLRCC. This is consistent with emerging studies indicating the existence of cell- and tissue-specific cysteine-omes, further emphasizing the need for characterization of diverse models. Our analysis provides a resource for understanding the proteomic adaptation to fumarate accumulation and a foundation for future efforts to exploit this knowledge for cancer therapy.

Indexed as

Cell Line, TumorCysteineFumarate HydrataseFumaratesHumansKidney NeoplasmsLeiomyomatosisNeoplastic Syndromes, HereditarySkin NeoplasmsUterine NeoplasmsCysteineFumarate HydrataseFumarateschemical biologyinborn error of metabolismmetabolismmitochondriaposttranslational modification (PTM)proteomicsredox signalingTCA cycletricarboxylic acid cycle (TCA cycle) (Krebs cycle)

Identifiers

PMID32820045
PMCPMC7521642
OpenAlexW3081346895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.